Le Wang

PROFILE

Homepage
No homepage is listed.
ORCID
No ORCID is listed.
Affiliations
No affiliations are listed.
Aliases
No aliases are listed.
Publication record
33 papers · 2,369 citations · H-index 16

PAPERS

Discovery of A-1331852, a First-in-Class, Potent, and Orally-Bioavailable BCL-XL Inhibitor
2020104 citationsauthor #1
Selective inhibition of the BD2 bromodomain of BET proteins in prostate cancer
2020296 citationsauthor #10
Discovery of N-ethyl-4-[2-(4-fluoro-2,6-dimethyl-phenoxy)-5-(1-hydroxy-1-methyl-ethyl)phenyl]-6-methyl-7-oxo-1H-pyrrolo[2,3-c]pyridine-2-carboxamide (ABBV-744), a BET bromodomain inhibitor with selectivity for the second bromodomain.
202091 citationsauthor #2
Abstract 931: Discovery of ABBV-744, a first-in-class highly BDII-selective BET bromodomain inhibitor
20184 citationsauthor #2
Discovery and optimization of novel constrained pyrrolopyridone BET family inhibitors.
20187 citationsauthor #7
Fragment-Based, Structure-Enabled Discovery of Novel Pyridones and Pyridone Macrocycles as Potent Bromodomain and Extra-Terminal Domain (BET) Family Bromodomain Inhibitors.
201756 citationsauthor #1
Preclinical Characterization of BET Family Bromodomain Inhibitor ABBV-075 Suggests Combination Therapeutic Strategies.
201796 citationsauthor #12
Discovery of N-(4-(2,4-Difluorophenoxy)-3-(6-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridin-4-yl)phenyl)ethanesulfonamide (ABBV-075/Mivebresib), a Potent and Orally Available Bromodomain and Extraterminal Domain (BET) Family Bromodomain Inhibitor.
2017118 citationsauthor #2
Methylpyrrole inhibitors of BET bromodomains.
201717 citationsauthor #3
Abstract 4718: ABBV-075, a novel BET family bromodomain inhibitor, represents a promising therapeutic agent for a broad spectrum of cancer indications
20168 citationsauthor #14
Abstract 4695: Functional group elaboration of a low molecular weight fragment to yield the novel BET family bromodomain inhibitor ABBV-075
20161 citationsauthor #2
Correction to Structure-Guided Design of a Series of MCL-1 Inhibitors with High Affinity and Selectivity.
20154 citationsauthor #2
Structure-guided design of a series of MCL-1 inhibitors with high affinity and selectivity.
2015142 citationsauthor #2
Exploiting selective BCL-2 family inhibitors to dissect cell survival dependencies and define improved strategies for cancer therapy
2015483 citationsauthor #24
Discovery of a Potent and Selective BCL-XL Inhibitor with in Vivo Activity.
2014268 citationsauthor #3
Structure-Guided Rescaffolding of Selective Antagonists of BCL-XL.
201436 citationsauthor #22
Derivatives of 8-carbamoyl-2- (pyrid-6-yl 2,3-disubstituted) -1,2,3,4-tetrahydroisoquinoline as apoptosis inducing agents for the treatment of cancer and immune and autoimmune disease
20120 citationsauthor #1
Investigation of novel 7,8-disubstituted-5,10-dihydro-dibenzo[b,e][1,4]diazepin-11-ones as potent Chk1 inhibitors.
200813 citationsauthor #2
Indoles substituted in position 7 as inhibitors of mcl-1
20080 citationsauthor #7
Structure-based design, synthesis, and biological evaluation of potent and selective macrocyclic checkpoint kinase 1 inhibitors.
200772 citationsauthor #2
A highly potent and selective farnesyltransferase inhibitor ABT-100 in preclinical studies
20058 citationsauthor #6
Imidazole and cyanophenyl farnesyl transferase inhibitors
20040 citationsauthor #3
Synthesis and biological evaluation of 1-benzyl-5-(3-biphenyl-2-yl-propyl)-1H-imidazole as novel farnesyltransferase inhibitor.
200412 citationsauthor #2
Design, synthesis, and biological activity of 4-[(4-cyano-2-arylbenzyloxy)-(3-methyl-3H-imidazol-4-yl)methyl]benzonitriles as potent and selective farnesyltransferase inhibitors.
200434 citationsauthor #1
Synthesis of 1H-pyridin-2-one derivatives as potent and selective farnesyltransferase inhibitors.
200411 citationsauthor #1
Synthesis and biological evaluation of 4-[(3-methyl-3H-imidazol-4-yl)-(2-phenylethynyl-benzyloxy)-methyl]-benzonitrile as novel farnesyltransferase inhibitor.
20033 citationsauthor #2
Discovery of potent imidazole and cyanophenyl containing farnesyltransferase inhibitors with improved oral bioavailability.
200319 citationsauthor #3
Synthesis and biological evaluation of 4-[3-biphenyl-2-yl-1-hydroxy-1-(3-methyl-3H-imidazol-4-yl)-prop-2-ynyl]-1-yl-benzonitrile as novel farnesyltransferase inhibitor.
200310 citationsauthor #2
Pyridone-containing farnesyltransferase inhibitors: synthesis and biological evaluation.
200366 citationsauthor #11
Potent, orally active heterocycle-based combretastatin A-4 analogues: synthesis, structure-activity relationship, pharmacokinetics, and in vivo antitumor activity evaluation.
2002394 citationsauthor #1
antiproliferative agents imidazole.
20000 citationsauthor #3
Antiproliferative imidazole active substances
20000 citationsauthor #1
Antiproliferants a base d'oxazolines substituees
19990 citationsauthor #8

TIMELINE

1999 0 citations

2000 0 citations

2002 394 citations

2003 98 citations

2004 57 citations

2005 8 citations

2007 72 citations

2008 13 citations

2012 0 citations

2014 304 citations

2015 629 citations

2016 9 citations

2017 287 citations

2018 11 citations

2020 491 citations

Le Wang

PROFILE

PAPERS

TIMELINE

COAUTHOR MAP

CONCEPT FOOTPRINT